SCHEMBL31089804

SCHEMBL31089804

Cn1cc(-c2cc3c(Cl)c(C=O)cnc3n2S(=O)(=O)c2ccccc2)cn1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDPK1 O15530 1/20 0.38
FGFR1 P11362 1/20 0.37
WNT1 P04628 1/20 0.37
GSK3B P49841 1/20 0.37
DYRK1A Q13627 1/20 0.37
CDK2 P24941 5/20 0.37
CCNT1 O60563 4/20 0.37
CCNB2 O95067 4/20 0.37
CCNE2 O96020 4/20 0.37
CDK1 P06493 4/20 0.37
CCNB1 P14635 4/20 0.37
CCNE1 P24864 4/20 0.37
CDK9 P50750 4/20 0.37
CDK5 Q00535 4/20 0.37
CDK5R1 Q15078 4/20 0.37
CCNB3 Q8WWL7 4/20 0.37
HDAC3 O15379 1/20 0.35
KDM1A O60341 1/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24165519 0.84 HDAC3 (0.40) PDPK1FGFR1WNT1GSK3BDYRK1A
SCHEMBL31089879 0.83 PDPK1 (0.35) PDPK1FGFR1WNT1GSK3BDYRK1A
SCHEMBL24165525 0.83 DCTPP1 (0.39) PDPK1FGFR1WNT1GSK3BDYRK1A
SCHEMBL15661963 0.82 PDPK1 (0.38) PDPK1FGFR1WNT1GSK3BDYRK1A
SCHEMBL24166208 0.82 ERN1 (0.42) PDPK1FGFR1WNT1GSK3BDYRK1A
SCHEMBL1156790 0.79 ERN1 (0.39) PDPK1FGFR1WNT1GSK3BDYRK1A
SCHEMBL1354815 0.79 CDK2 (0.39) CDK2CCNT1CCNB2CCNE2CDK1
SCHEMBL21470471 0.78 FGFR1 (0.42) PDPK1FGFR1WNT1GSK3BDYRK1A
SCHEMBL17289609 0.78 PDPK1 (0.40) PDPK1FGFR1WNT1GSK3BDYRK1A
SCHEMBL31089900 0.78 WNT1 (0.36) PDPK1WNT1GSK3BDYRK1ACDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240300948-A1 Heterocyclic Compounds As Kinase Inhibitors INCYTE CORPORATION 2024-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300948-A1 Heterocyclic Compounds As Kinase Inhibitors JAK2, JAK1, JAK3 PDPK1 123/4885FGFR1 523/4885WNT1 1666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.